TY - JOUR
T1 - Serum triglycerides predict first cardiovascular events in diabetic patients with hypercholesterolemia and retinopathy
AU - Tada, Hayato
AU - Kawashiri, Masa aki
AU - Nomura, Akihiro
AU - Yoshimura, Kenichi
AU - Itoh, Hiroshi
AU - Komuro, Issei
AU - Yamagishi, Masakazu
N1 - Funding Information:
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Hayato Tada reports payments for lectures from Astellas Pharma Inc., Amgen Astellas BioPharma K.K., Bayer Yakuhin Ltd, Sanofi K.K., Takeda Pharmaceutical Company Ltd, Kowa Pharmaceutical Co. Ltd, Mitsubishi Tanabe Pharma and research grant from Sanofi K.K.. Akihiro Nomura has nothing to disclose. Masa-aki Kawashiri reports payments for lectures from Shionogi & Co., Ltd, Daiichi-Sankyo Co., Ltd, Astellas Pharma Inc., AstraZeneca K.K., Kissei Pharmaceutical Co., Ltd, Bayer Yakuhin Ltd, Kyowa Hakko Kirin Co., Ltd. Masakazu Yamagishi reports research grants from MSD K.K., Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd, Otsuka Pharmaceutical Co., Ltd, and payments for lectures from Astellas Pharma Inc., Daiichi-Sankyo Co., Ltd, Shionogi and Co., Ltd, Kowa Co., Ltd. Hiroshi Itoh reports grants and personal fees from Shionogi and Co., Ltd, during the conduct of the study; grants and personal fees from Takeda Pharmaceutical Company Ltd, Nippon Boehringer Ingelheim Co., Ltd, Daiichi Sankyo Company Ltd, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Taisho Toyama Pharmaceutical Co., Ltd, grants from Sumitomo Dainippon Pharma Co., Ltd, Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd, Teijin Pharma Ltd, Mochida Pharmaceutical Co., Ltd, Ono Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, Eli Lilly Japan K.K., personal fees from Nipro Corporation, SBI Pharmaceuticals Co., Ltd, outside the submitted work. Issei Komuro reports personal fees from Shionogi and Co., Ltd, during the conduct of the study; grants and personal fees from Takeda Pharmaceutical Company Ltd, Nippon Boehringer Ingelheim Co., Ltd, Astellas Pharma Inc., Daiichi Sankyo Company Ltd, Otsuka Pharmaceutical Co., Ltd, grants from MSD K.K., Shionogi and Co., Ltd, GlaxoSmithKline K.K., Sanofi K.K., Genzyme Japan K.K., Sumitomo Dainippon Pharma Co., Ltd, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb Company, outside the submitted work.
PY - 2018/1/1
Y1 - 2018/1/1
N2 - Aims: Low-density lipoprotein cholesterol predicts cardiovascular events in patients with diabetes. However, it is uncertain whether serum triglycerides level is also associated with an occurrence of future cardiovascular events in diabetic patients. We aimed to test whether serum triglycerides is associated with first cardiovascular events in diabetic patients. Methods and results: We recruited 5042 participants with diabetes mellitus from the standard versus intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY), multicenter, prospective, randomized, open-label, blinded-endpoint study. Median follow-up was three years. We evaluated an association of serum triglycerides with first cardiovascular events in cox-regression hazard models adjusted by age, sex, hypertension, current smoking, low-density lipoprotein cholesterol, and body mass index. Cardiovascular events were defined as (a) major adverse cardiac events including myocardial infarction, stroke, or cardiac death; and (b) cardiovascular diseases including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Serum triglycerides were associated with major adverse cardiac events (adjusted hazard ratio: 1.021 per 10 mg/dl; 95% confidence interval: 1.007-1.035; p=0.0025) and cardiovascular diseases (adjusted hazard ratio: 1.023 per 10 mg/dl; 95% confidence interval: 1.013-1.034; p=0.0000077). Comparing the top quintile (>185 mg/dl) with the bottom quintile (<79 mg/dl), the adjusted hazard ratio increased 1.89 (95% confidence interval: 1.03-2.80, p=0.04) for major adverse cardiac events, and 1.90 (95% confidence interval: 1.18-3.07, p=0.007) for cardiovascular diseases. There were no overall interactions of triglycerides and treatment assignment (standard/intensive statins) on both outcomes (p-trend=0.33 for major adverse cardiac events, p-trend=0.62 for cardiovascular diseases). Conclusions: Serum triglycerides were associated with first cardiovascular events among high-risk diabetes patients with hypercholesterolemia and retinopathy.
AB - Aims: Low-density lipoprotein cholesterol predicts cardiovascular events in patients with diabetes. However, it is uncertain whether serum triglycerides level is also associated with an occurrence of future cardiovascular events in diabetic patients. We aimed to test whether serum triglycerides is associated with first cardiovascular events in diabetic patients. Methods and results: We recruited 5042 participants with diabetes mellitus from the standard versus intEnsive statin therapy for hypercholesteroleMic Patients with diAbetic retinopaTHY (EMPATHY), multicenter, prospective, randomized, open-label, blinded-endpoint study. Median follow-up was three years. We evaluated an association of serum triglycerides with first cardiovascular events in cox-regression hazard models adjusted by age, sex, hypertension, current smoking, low-density lipoprotein cholesterol, and body mass index. Cardiovascular events were defined as (a) major adverse cardiac events including myocardial infarction, stroke, or cardiac death; and (b) cardiovascular diseases including myocardial infarction, unstable angina, ischemic stroke, or large artery disease or peripheral arterial disease. Serum triglycerides were associated with major adverse cardiac events (adjusted hazard ratio: 1.021 per 10 mg/dl; 95% confidence interval: 1.007-1.035; p=0.0025) and cardiovascular diseases (adjusted hazard ratio: 1.023 per 10 mg/dl; 95% confidence interval: 1.013-1.034; p=0.0000077). Comparing the top quintile (>185 mg/dl) with the bottom quintile (<79 mg/dl), the adjusted hazard ratio increased 1.89 (95% confidence interval: 1.03-2.80, p=0.04) for major adverse cardiac events, and 1.90 (95% confidence interval: 1.18-3.07, p=0.007) for cardiovascular diseases. There were no overall interactions of triglycerides and treatment assignment (standard/intensive statins) on both outcomes (p-trend=0.33 for major adverse cardiac events, p-trend=0.62 for cardiovascular diseases). Conclusions: Serum triglycerides were associated with first cardiovascular events among high-risk diabetes patients with hypercholesterolemia and retinopathy.
KW - Cardiovascular disease
KW - Residual risk
KW - Statin
KW - Triglycerides
UR - http://www.scopus.com/inward/record.url?scp=85053420567&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053420567&partnerID=8YFLogxK
U2 - 10.1177/2047487318796989
DO - 10.1177/2047487318796989
M3 - Article
C2 - 30160521
AN - SCOPUS:85053420567
SN - 2047-4873
VL - 25
SP - 1852
EP - 1860
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 17
ER -